OCUGEN INC. - COMMON STOCK

Ocugen Announces OCU400 Receives Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Retinitis Pigmentosa Associated with RHO Mutations

19 Dec 2023 07:30:00 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410—Modifier Gene Therapy—for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

13 Dec 2023 07:30:14 By Nasdaq GlobeNewswire

Ocugen CEO to Present at NobleCon19 – Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference

29 Nov 2023 07:30:12 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating the Safety and Efficacy of OCU410ST—Modifier Gene Therapy—for Stargardt Disease

10 Nov 2023 07:30:37 By Nasdaq GlobeNewswire

Ocugen Provides Business Update with Third Quarter 2023 Financial Results

09 Nov 2023 06:30:00 By Nasdaq GlobeNewswire

Ocugen CSO to Participate in 4th Annual Dry AMD Therapeutic Development Summit

07 Nov 2023 07:45:14 By Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Thursday, November 9 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2023 Financial Results

02 Nov 2023 07:30:06 By Nasdaq GlobeNewswire

Ocugen Mucosal Vaccine Candidate OCU500 Selected by NIH/NIAID Project NextGen for Inclusion in Clinical Trials

10 Oct 2023 06:30:48 By Nasdaq GlobeNewswire

Ocugen to Present at the 2023 Cell & Gene Meeting on the Mesa

04 Oct 2023 07:00:20 By Nasdaq GlobeNewswire

Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference

29 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference

27 Sep 2023 19:30:50 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board

21 Sep 2023 07:30:40 By Nasdaq GlobeNewswire

Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023

20 Sep 2023 08:00:24 By Nasdaq GlobeNewswire

Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)

13 Sep 2023 08:15:19 By Nasdaq GlobeNewswire

Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023

12 Sep 2023 19:30:24 By Nasdaq GlobeNewswire

Ocugen Provides Business Update with Second Quarter 2023 Financial Results

21 Aug 2023 16:32:21 By Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results

18 Aug 2023 16:39:06 By Nasdaq GlobeNewswire

Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly

30 Jun 2023 08:00:19 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders

09 Jun 2023 16:05:12 By Nasdaq GlobeNewswire

Ocugen, Inc. Announces Business Advisory Board

05 Jun 2023 07:02:25 By Nasdaq GlobeNewswire